Journal Mobile Options
Table of Contents
Vol. 105, No. 2, 2001
Issue release date: May 2001
Acta Haematol 2001;105:106–108
(DOI:10.1159/000046545)

Successful Treatment of Angioimmunoblastic Lymphadenopathy with Dysproteinemia-Type T-Cell Lymphoma with Fludarabine

Tsatalas C. · Margaritis D. · Kaloutsi V. · Martinis G. · Kotsianidis I. · Bourikas G.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC: A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 1994;84:1361–1392.
  2. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J: Lymphoma classification – from controversy to consensus; the REAL and WHO classification of lymphoid neoplasms. Ann Oncol 2000;11(suppl 1):3–10.
  3. Sallah S, Gagnon GA: Angioimmunoblastic lymphadenopathy with dysproteinemia: Emphasis on pathogenesis and treatment. Acta Haematol 1998;99:57–64.
  4. Ong ST, Koeppen H, Larson RA, Olopade OI: Successful treatment of angioimmunoblastic lymphadenopathy with dysproteinemia with fludarabine. Blood 1996;88:2354–2355.

    External Resources

  5. Hast R, Jacobsson B, Petrescu A, Hjalmar V: Successful treatment with fludarabine in two cases of angioimmunoblastic lymphadenopathy with dysproteinemia. Leuk Lymphoma 1999;34:597–601.
  6. Witzig TE, Weitz JJ, Lundberg JH, Tefferi A: Treatment of refractory T-cell chronic lymphocytic leukemia with purine nucleoside analogues. Leuk Lymphoma 1994;14:137–139.

    External Resources



Pay-per-View Options
Direct payment This item at the regular price: USD 33.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 23.00